Cancer Monoclonal Antibodies Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Market Overview

The cancer monoclonal antibodies market is expected to witness a CAGR of 9.2% during the forecast period. Certain factors that are driving the market growth include the growing prevalence of cancer, increasing investment in R&D of genomic studies, and rising advancements in and preference toward the specificity of monoclonal antibodies to target cancer.

According to the World Health Organization, cancer is the second leading cause of death worldwide, accounting for an estimated 9.6 million deaths, or one in six deaths, in the year 2018. Lung cancer, prostate cancer, colorectal cancer, and liver cancer are the most common types of cancer in men, while breast cancer, colorectal cancer, lung cancer, cervical cancer and thyroid cancer are the most common among women. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.

However, following the regulatory guidelines for monoclonal antibodies related to cancer is a highly rigorous process in most of the regions, globally. The guidelines provide a comprehensive description of the manufacturing processes including quality, good manufacturing practices, process validation, potential for degradation, and the need for stability studies. A stringent regulatory scenario exists globally, such as the US FDA, the European Medicines Agency (EMA), and the Korean FDA. Similar to biologics, biosimilar also faces similar restrictions for getting the approval of monoclonal antibodies in the market. Since it is a time-consuming process, it is considered as one of the major hindering factors for this market. Other factors that restrains the growth of the cancer monoclonal antibodies market are long duration of research and development before clinical trials and the rise in the failures of mAbs in clinical trials.

Scope of the Report

As per the scope of the report, monoclonal antibodies are highly specific to cancer cells, as they bind to the proteins on their surface and stimulate an immune response. This market consists of several types of monoclonal antibodies and much more in the pipeline. The cancer monoclonal antibodies market is segmented by types of a monoclonal antibody, monoclonal antibody therapies, application and geography.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Trastuzumab (Herceptin) is Expected to Hold Significant Market Share in Monoclonal Antibody Therapies

Trastuzumab (Herceptin) is a monoclonal antibody used to treat breast cancer. It is also an approved first-line treatment for HER2+ metastatic cancer of the stomach or gastro-oesophagal junction. According to Roche’s (manufacturer of the drug) annual report 2019, the annual sales revenue generated from the drug Herceptin (oncology) was 69,82 (in million Swiss francs) in 2018 and 60,39 (in million Swiss francs). The country witnessed continued growth, mainly, due to the longer duration of treatment in combination with Perjeta.

However, the common side effects (fever, infection, cough, and rash, among others) and severe side effects (heart failure, allergic reaction, and lung disorders) are associated with the drug. The drug may also result in unnecessary issues for the baby if taken during pregnancy. These side effects may affect the adoption rate and, hence, may act as an inhibiting factor.

To understand key trends, Download Sample Report